Trial Profile
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- 29 Jan 2020 Status changed from active, no longer recruiting to completed.
- 03 Nov 2018 Planned End Date changed from 1 Nov 2018 to 1 Oct 2020.
- 03 Nov 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2019.